Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Cut 400 to 500 Workers in Europe
August 2, 2013
- Daiichi Sankyo Sales Up 4% in First Quarter, Profits Down due to Ranbaxy Business Slump
August 2, 2013
- Takeda April-June Sales Up 3%, but Operating Profit Logs Double-Digit Fall
August 2, 2013
- Sanofi Files NDA for Prostate Cancer Treatment Cabazitaxel in Japan
August 2, 2013
- Prospects for World’s 1st FD Treatment Remain Unclear; Success Will Depend on Raising Awareness, Role of Endoscopy
August 2, 2013
- Pfizer, Takeda Launch RA Treatment Xeljanz, Prepare for Promoting Proper Use of Drug
August 1, 2013
- Takeda Paid 40 billion Yen to Healthcare Professionals in FY2012
August 1, 2013
- 2 Beijing-Based Wholesalers Could Serve as Point of Contact for Japanese Drug Makers: Mr Yoda of Medipal Holdings
August 1, 2013
- PII Study of Renal Anemia Treatment Codeveloped by FibroGen Starts in Japan: Astellas
August 1, 2013
- Sanofi K.K.’s Payments to Healthcare Professionals Total 9.8 Billion Yen in 2012
July 31, 2013
- Ex-Novartis Employee Had Access to Pre-Locked Data: Third-Party Probe
July 31, 2013
- Novartis Paid 23.6 Billion Yen to Doctors, Medical and Research Institutions in 2012
July 31, 2013
- Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
July 30, 2013
- Arbekacin Inhalation Solution Enters PI Study in US: Meiji Seika Pharma
July 30, 2013
- Medipal, Mitsubishi Acquire Shares in Chinese Pharma Wholesaler for 8 Billion Yen
July 30, 2013
- Janssen Files NDA for Prostate Cancer Treatment Abiraterone in Japan
July 30, 2013
- Kyowa Kirin’s 1st Half Sales Up 2.1%, but Mainstay Nesp Slumps 7%
July 29, 2013
- Interim Analysis of Multinational PIII Study of Orteronel Shows No Improvement of OS in Patients with mCRPC: Takeda
July 29, 2013
- Bell Medical, inVentiv to Provide Promotion and PMS Support Services
July 26, 2013
- Chugai Sales Up 8.4% Due to Increase in Cancer Treatment, Overseas Sales
July 26, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…